ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0684

Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Abstract Number: 0685

Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
Abstract Number: 0686

Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
Abstract Number: 0687

Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
Abstract Number: 0688

Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
Abstract Number: 0689

Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2
Abstract Number: 0690

Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy
Abstract Number: 0691

Recognizing the New Disorder “Idiopathic Hypocryoglobulinaemia” in Patients with Previously Unidentified Clinical Conditions
Abstract Number: 0692

Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
Abstract Number: 0693

Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus
Abstract Number: 0694

Off-label Use of Biologics in Urticarial Vasculitis: A European Cohort Study
Abstract Number: 0695

Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Abstract Number: 0696

Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Abstract Number: 0697

Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis
Abstract Number: 0698

Differentiating Large Vessel Vasculitis from Vasculitis Mimickers in a Real World Setting: Clinical Presentation, Laboratory Tests and Radiographic Findings

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].